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major adverse cardiac events (MACE) was much higher in patients
treated with DES. We found that there was initially a benefit in terms
of MACE in patients who received DES compared with the benefit
seen in patients receiving BMS, but thereafter we noticed a late
catch-up phenomenon (Fig. 1).
In this regard, Chu et al. (4) in a small study showed that
although there were no differences in DES and BMS used for the
treatment of SVG disease, the incidence of MACE increased from
6 months to 1 year after PCI in the BMS group, and the DES
group had a much more pronounced increase in MACE in the
same time frame. The secondary post-hoc data from the delayed
RRISC (Reduction of Restenosis In Saphenous vein grafts with
Cypher Stent) trial (5) also showed that over a median follow-up
of 32 months, use of BMS was associated with significantly lower
long-term mortality than the use of DES in SVG disease. The use
of DES in the SVG disease needs to be re-examined.
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Reply
We really welcome the additional data provided by Dr. Bansal and
colleagues over the mid- and long-term outcome of drug-eluting
stents (DES) in diseased saphenous vein grafts (SVGs). We also
appreciate the words of caution expressed by the authors and
focused on a more careful use of DES in this type of lesion. Indeed,
their data, as well as our long-term data from the DELAYED
RRISC (Death and Events at Long-term follow-up AnalYsis:
Extended Duration of the Reduction of Restenosis In Saphenous
vein grafts with Cypher stent) trial (1), and the data from Chu
et al. (2), all point out that in the long term DES seem not to
maintain the possible advantages shown in the midterm. Another
additional study (a sub-study of the large prospective STENT
[Strategic Transcatheter Evaluation of New Therapies] registry),
recently presented as an abstract, also showed no differences
between DES and bare-metal stents in SVGs (3). To our knowl-
edge, while there are some data showing benefit of DES over
bare-metal stents in the midterm (up to 6 to 9 months), there are
no registries showing the same benefit in the long term (1 year).
The only long-term study is the one previously mentioned, and all
show a similar trend without clear advantage of DES over
bare-metal stents.
However, we have to underline some issues related to all these
analyses. On the one hand, our data are focused only on sirolimus-
eluting stents and not on other types of DES (1). On the other
hand, the data of Dr. Bansal and colleagues, of Chu et al. (2), and
of the STENT registry (3) were based on analyses encompassing
different types of DES. Whether their results were mainly driven
by a suboptimal performance of one type of DES over the others
or whether there is a “class-effect” of DES in SVG, this cannot be
evinced by the data provided. New prospective studies are under-
going in order to also offer additional data on other types of DES,
such as polymeric paclitaxel-eluting stents (4). In addition, as all of
these studies analyzed de-novo lesions in SVGs, we have a total
lack of data on the way DES perform in restenotic SVG lesions.
While waiting for a conclusive large and well-powered random-
ized trial of DES versus bare-metal stents in SVGs, in our opinion
the use of DES in this lesion subset in daily life clinical practice
should be discouraged (unless prospectively evaluated in a study).
If there is a willingness to implant a DES in a diseased SVG, this
should be firmly discussed with the patient, and a careful assess-
ment of the possible advantages and risks related to the implan-
tation of this device should be cautiously evaluated. Moreover, we
welcome interventional cardiologists that implanted DES in SVGs
to try to collect long-term data on their patients in order to provide
additional data to the scientific community, like Dr. Bansal et al.
remarkably did in their letter.
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The Balance of Risks and
Benefits of Drug-Eluting
Versus Bare-Metal Stents
In a recent article entitled “Stent Thrombosis, Myocardial Infarc-
tion, and Death After Drug-Eluting and Bare-Metal Stent Cor-
onary Interventions,” Jensen et al. (1) added another piece of
evidence to the “late stent thrombosis story” based on registry data
of 12,000 patients. Similar to the findings of BASKET-LATE
(Late Clinical Events Related to Late Stent Thrombosis After
Stopping Clopidogrel) (2) and the Swedish registry (3) as well as
several meta-analyses recently published, they found no excess
mortality overall but an excess in very late (12 months) stent
thrombosis and myocardial infarction (MI). In fact, according
to their Figures 1A and 1D (1 ), the event curves for MI and
stent thromboses seem to diverge already after 6 to 9 months as
in BASKET-LATE and the Swedish registry, which were per-
formed before the publication of the Academic Research Consor-
tium (4) definition of very late as being after 1 year. This stresses
the need to separate findings of thrombotic events in the first (6 or)
12 months from later events and suggests not to lump them
together in overall conclusions as in the report by Jensen et al. (1).
Thus, it seems not quite correct, if the authors write in their
discussion that their findings differed from those of BASKET-
LATE, particularly since that study only reported “late” stent
thrombosis and related clinical events after 6 months.
The most important point in their study is, however, the
balance of risks and benefits of drug-eluting versus bare-metal
stents. Unfortunately, they do not present data on clinical events
related to restenosis/target lesion revascularization that would have
to be weighed against late clinical events related to very late stent
thrombosis as has recently been described by Stone et al. (5): the
first year excess in death/MI due to restenosis after bare-metal
stent implantation was exactly balanced by a second and third year
excess in the same hard events due to stent thrombosis of
drug-eluting-stent-treated patients. Again, a similar balance was
calculated from the BASKET/BASKET-LATE experience (2).
Since the rate of death/MI due to restenosis is much lower than
that due to late stent thrombosis, it would be most helpful to the
reader of the article by Jensen et al. (1) if such a balance could be
specified in “hard” clinical events based on this Danish registry. A
major limitation, however, will be the short period of very late
follow-up of only 3 months. Still, the patient and his treating
physician will have to decide upon such outcome data: long-term
clinical—death or MI—risks and benefits.
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Reply
We appreciate the interest of Dr. Pfisterer and colleagues in our
registry study on stent thrombosis, myocardial infarction, and
death after drug-eluting stent (DES) and bare-metal stent (BMS)
coronary interventions (1).
Dr. Pfisterer and colleagues have the following comments to our
study:
1. Early and late thrombotic events should be separated
It is our opinion that the overall conclusions should include the
entire study period and not only a post-hoc selected period.
Moreover, as we are dealing with registry data, we find it
important to focus on total mortality as the most reliable
parameter. Therefore, we concluded that DES, as compared
with BMS, was a safe intervention in a population with 15
months follow-up (1). We are aware that the event curves for
stent thrombosis and myocardial infarction diverge in favor of
the BMS group and, as Dr. Pfisterer and colleagues, we
acknowledge that late stent thrombosis is a problem, albeit
numerically small, after DES implantation. Interestingly, the
event curves of stent thrombosis and MI seem to cross at a later
time point in the Western Denmark Heart registry than in the
Swedish Coronary Angiography and Angioplasty registry (2),
possibly due to a longer clopidogrel treatment time in Den-
mark.
2. No data on clinical events related to restenosis/target lesion
revascularization
We agree that these data are of great interest. It is, however, a
time-consuming task to get a detailed clinical assessment of
reinterventions in our 12,000 patient cohort. Hopefully, we
will be able to describe the delicate safety balance between
stent thrombosis and target lesion revascularization in a future
publication.
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